Related Experiment Video
Updated: Aug 30, 2025

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Microbiota profiles in pre-school children with respiratory infections: Modifications induced by the oral bacterial
Susanna Esposito1, Stefania Ballarini2, Alberto Argentiero1
1Pediatric Clinic, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Abstract:
To describe microbiota profiles considering potential influencing factors in pre-school children with recurrent respiratory tract infections (rRTIs) and to evaluate microbiota changes associated with oral bacterial lysate OM-85 treatment, we analyzed gut and nasopharynx (NP) microbiota composition in patients included in the OM-85-pediatric rRTIs (OMPeR) clinical trial (https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002705-19/IT). Relative percentage abundance was used to describe microbiota profiles in all the available biological specimens, grouped by age, atopy, and rRTIs both at inclusion (T0) and at the end of the study, after treatment with OM-85 or placebo (T1). At T0, Firmicutes and Bacteriodetes were the predominant genera in gut and Proteobacteria, Firmicutes, and Actinobacteria were the predominant genera in NP samples. Gut microbiota relative composition differed with age (<2 vs. ≥2 years) for Firmicutes, Proteobacteria, Actinobacteria (phyla) and Bifidobacterium, Ruminococcus, Lachnospiraceae (genera) (p < 0.05). Moraxella was more enriched in the NP of patients with a history of up to three RTIs. Intra-group changes in relative percentage abundance were described only for patients with gut and NP microbiota analysis available at both T0 and T1 for each study arm. In this preliminary analysis, the gut microbiota seemed more stable over the 6-month study in the OM-85 group, whose mean age was lower, as compared to the placebo group (p = 0.004). In this latter group, the relative abundance of Bacteroides decreased significantly in children ≥2 years. Some longitudinal significant differences in genera relative abundance were also detected in children of ≥2 years for NP Actinobacteria, Haemophilus, and Corynebacterium in the placebo group only. Due to the small number of patients in the different sub-populations, we could not identify significant differences in the clinical outcome and therefore no associations with microbiota changes were searched. The use of bacterial lysates might play a role in microbiota rearrangement, but further data and advanced analysis are needed to prove this in less heterogeneous populations with higher numbers of samples considering the multiple influencing factors such as delivery method, age, environment, diet, antibiotic use, and type of infections to ultimately show any associations with prevention of rRTIs.
Insights
This study explored gut and nasopharyngeal microbiota in preschool children with recurrent respiratory tract infections (rRTIs). Oral bacterial lysate OM-85 treatment showed potential for microbiota stability, but further research is needed.
Area of Science:
- Microbiome research
- Pediatric infectious diseases
- Immunology
Background:
- Recurrent respiratory tract infections (rRTIs) are common in preschool children.
- Microbiota composition in the gut and nasopharynx may influence rRTI susceptibility.
- Oral bacterial lysates are explored for immune modulation and infection prevention.
Purpose of the Study:
- To characterize gut and nasopharyngeal microbiota in children with rRTIs.
- To investigate the impact of oral bacterial lysate OM-85 on microbiota composition.
- To identify factors influencing microbiota profiles in this pediatric population.
Main Methods:
- Analysis of gut and nasopharynx microbiota composition in the OMPeR clinical trial.
- Microbiota profiling using relative percentage abundance at baseline (T0) and end-of-study (T1).
- Stratification of data by age, atopy, rRTI history, and treatment group (OM-85 vs. placebo).
Main Results:
- Gut microbiota dominated by Firmicutes and Bacteroidetes; nasopharynx by Proteobacteria, Firmicutes, and Actinobacteria at baseline.
- Microbiota composition varied with age and was influenced by rRTI history (e.g., Moraxella enrichment).
- Preliminary analysis suggested greater gut microbiota stability in the OM-85 group compared to placebo, particularly in younger children.
Conclusions:
- Oral bacterial lysate OM-85 may influence gut microbiota stability in children with rRTIs.
- Age and infection history are significant factors shaping pediatric microbiota.
- Larger, more homogeneous studies are required to confirm findings and explore associations with clinical outcomes.

